180 related articles for article (PubMed ID: 27655666)
21. Targeted Therapy for Neuroblastoma: ALK Inhibitors.
Schulte JH; Schulte S; Heukamp LC; Astrahantseff K; Stephan H; Fischer M; Schramm A; Eggert A
Klin Padiatr; 2013 Nov; 225(6):303-8. PubMed ID: 24166094
[TBL] [Abstract][Full Text] [Related]
22. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
Pacenta HL; Macy ME
Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456
[TBL] [Abstract][Full Text] [Related]
23. Peptides derived from the dependence receptor ALK are proapoptotic for ALK-positive tumors.
Aubry A; Galiacy S; Ceccato L; Marchand C; Tricoire C; Lopez F; Bremner R; Racaud-Sultan C; Monsarrat B; Malecaze F; Allouche M
Cell Death Dis; 2015 May; 6(5):e1736. PubMed ID: 25950466
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines.
Brands RC; Herbst F; Hartmann S; Seher A; Linz C; Kübler AC; Müller-Richter UDA
Clin Oral Investig; 2016 Dec; 20(9):2325-2332. PubMed ID: 26846923
[TBL] [Abstract][Full Text] [Related]
25. Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells.
Aveic S; Pantile M; Seydel A; Esposito MR; Zanon C; Li G; Tonini GP
Oncotarget; 2016 Feb; 7(5):5646-63. PubMed ID: 26735175
[TBL] [Abstract][Full Text] [Related]
26. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
Berlak M; Tucker E; Dorel M; Winkler A; McGearey A; Rodriguez-Fos E; da Costa BM; Barker K; Fyle E; Calton E; Eising S; Ober K; Hughes D; Koutroumanidou E; Carter P; Stankunaite R; Proszek P; Jain N; Rosswog C; Dorado-Garcia H; Molenaar JJ; Hubank M; Barone G; Anderson J; Lang P; Deubzer HE; Künkele A; Fischer M; Eggert A; Kloft C; Henssen AG; Boettcher M; Hertwig F; Blüthgen N; Chesler L; Schulte JH
Mol Cancer; 2022 Jun; 21(1):126. PubMed ID: 35689207
[TBL] [Abstract][Full Text] [Related]
27. Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-α-independent apoptosis.
Eschenburg G; Eggert A; Schramm A; Lode HN; Hundsdoerfer P
Cancer Res; 2012 May; 72(10):2645-56. PubMed ID: 22491673
[TBL] [Abstract][Full Text] [Related]
28. Development of treatment strategies for advanced neuroblastoma.
Hara J
Int J Clin Oncol; 2012 Jun; 17(3):196-203. PubMed ID: 22588779
[TBL] [Abstract][Full Text] [Related]
29. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.
Siaw JT; Wan H; Pfeifer K; Rivera VM; Guan J; Palmer RH; Hallberg B
Oncotarget; 2016 May; 7(20):29011-22. PubMed ID: 27049722
[TBL] [Abstract][Full Text] [Related]
30. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
Passoni L; Longo L; Collini P; Coluccia AM; Bozzi F; Podda M; Gregorio A; Gambini C; Garaventa A; Pistoia V; Del Grosso F; Tonini GP; Cheng M; Gambacorti-Passerini C; Anichini A; Fossati-Bellani F; Di Nicola M; Luksch R
Cancer Res; 2009 Sep; 69(18):7338-46. PubMed ID: 19723661
[TBL] [Abstract][Full Text] [Related]
31. A simple, highly visual in vivo screen for anaplastic lymphoma kinase inhibitors.
Rodrigues FS; Yang X; Nikaido M; Liu Q; Kelsh RN
ACS Chem Biol; 2012 Dec; 7(12):1968-74. PubMed ID: 22985331
[TBL] [Abstract][Full Text] [Related]
32. Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human
Wang HQ; Halilovic E; Li X; Liang J; Cao Y; Rakiec DP; Ruddy DA; Jeay S; Wuerthner JU; Timple N; Kasibhatla S; Li N; Williams JA; Sellers WR; Huang A; Li F
Elife; 2017 Apr; 6():. PubMed ID: 28425916
[TBL] [Abstract][Full Text] [Related]
33. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.
Redaelli S; Ceccon M; Antolini L; Rigolio R; Pirola A; Peronaci M; Gambacorti-Passerini C; Mologni L
Oncotarget; 2016 Nov; 7(45):72886-72897. PubMed ID: 27662658
[TBL] [Abstract][Full Text] [Related]
34. Targeting inhibitors of apoptosis in oral squamous cell carcinoma in vitro.
Scheurer MJJ; Seher A; Steinacker V; Linz C; Hartmann S; Kübler AC; Müller-Richter UDA; Brands RC
J Craniomaxillofac Surg; 2019 Oct; 47(10):1589-1599. PubMed ID: 31387829
[TBL] [Abstract][Full Text] [Related]
35. Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma.
Satoh S; Takatori A; Ogura A; Kohashi K; Souzaki R; Kinoshita Y; Taguchi T; Hossain MS; Ohira M; Nakamura Y; Nakagawara A
Sci Rep; 2016 Sep; 6():32682. PubMed ID: 27604320
[TBL] [Abstract][Full Text] [Related]
36. TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.
Amin AD; Li L; Rajan SS; Gokhale V; Groysman MJ; Pongtornpipat P; Tapia EO; Wang M; Schatz JH
Oncotarget; 2016 Apr; 7(17):23715-29. PubMed ID: 27009859
[TBL] [Abstract][Full Text] [Related]
37. PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
Geng X; Xie L; Xing H
Technol Cancer Res Treat; 2016 Oct; 15(5):716-22. PubMed ID: 26224681
[TBL] [Abstract][Full Text] [Related]
38. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
Opel D; Naumann I; Schneider M; Bertele D; Debatin KM; Fulda S
Clin Cancer Res; 2011 May; 17(10):3233-47. PubMed ID: 21355080
[TBL] [Abstract][Full Text] [Related]
39. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.
Chen Y; Wu J; Wang A; Qi Z; Jiang T; Chen C; Zou F; Hu C; Wang W; Wu H; Hu Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Liu Q; Liu J
Eur J Med Chem; 2017 Oct; 139():674-697. PubMed ID: 28850922
[TBL] [Abstract][Full Text] [Related]
40. Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice.
Shekhar TM; Burvenich IJG; Harris MA; Rigopoulos A; Zanker D; Spurling A; Parker BS; Walkley CR; Scott AM; Hawkins CJ
BMC Cancer; 2019 Sep; 19(1):924. PubMed ID: 31521127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
